Overview

Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382

Status:
Terminated

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics (what the body does to the medication) and antiviral activity of JNJ-47910382 when administered in different dosing regimens in Caucasian genotype-1 chronic HCV-infected patients.

Phase:

Phase 1

Details

Lead Sponsor:

Janssen R&D Ireland

Treatments:

Antiviral Agents